Pharvaris N.V. Prices $115M Public Offering to Fund Late-Stage Clinical Programs
PHVS has more than doubled off its 52-week low of $14.585 on elevated volume (2.6× avg).
Summary
Pharvaris N.V. has priced an underwritten public offering of 3.87 million ordinary shares at $29.68 per share, raising approximately $115 million before expenses, with potential for an additional $17.25 million if underwriters exercise their option.
Key Events · Financing and Capital Events · PHVS
-
Offering Priced
Pharvaris N.V. priced an underwritten public offering of 3,874,664 ordinary shares at $29.68 per share.
-
Capital Raised
The offering is expected to generate approximately $115 million in gross proceeds, with potential for an additional $17.25 million if underwriters fully exercise their option to purchase 581,199 shares, bringing the total to $132.25 million.
-
Strategic Use of Proceeds
Funds will primarily support late-stage clinical programs, expand U.S. sales and marketing teams, and cover general working capital, extending the cash runway into the first half of 2028.
-
Share Dilution
The offering represents a potential dilution of approximately 6.83% of the company's outstanding shares if the underwriters' option is fully exercised.
Analysis · PHVS · Life Sciences
This 424B5 filing finalizes the terms of the previously announced public offering, securing substantial capital for Pharvaris N.V. The offering, priced at $29.68 per share, is near the company's 52-week high, indicating strong market confidence. The proceeds, potentially reaching $132.25 million with the full exercise of the underwriters' option, are crucial for funding late-stage clinical programs, expanding sales and marketing efforts in the U.S., and covering general corporate purposes. This capital infusion is expected to extend the company's cash runway into the first half of 2028, significantly de-risking its operational timeline. While the offering will result in approximately 6.83% dilution for existing shareholders, the ability to raise such a significant amount at a favorable price point is a positive development for the company's long-term strategic goals, especially for a life sciences company with ongoing R&D.
At the time of this filing, PHVS was trading at $30.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $14.59 to $31.47. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.